Enveda’s latest fundraising round pegged at $311 million

Enveda’s latest fundraising round was identified at $311 million, with the capital intended to help get medicines to people. The company describes its technology as a “sequencer” for life’s chemical code, built to identify molecules in biological samples and determine what they do. It estimated that about 400,000 compounds have been discovered, compared with an expected total of 1 billion to 10 billion, and said 99% of what makes up people, tomatoes or samples from the Amazon rainforest remains a mystery to science.

Enveda has chosen to make and own drugs. The company’s representative argued that this is how large companies in the sector have been built and that they should make drugs that matter, citing estimates that GLP-1-related forward sales multiples account for something like 70% of Lilly’s enterprise value and 80% of Novo’s; the representative also cited about 30% of Sanofi’s, describing it as “half of one,” a drug called Dupixent.